Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jan 1:278:542-555.
doi: 10.1016/j.jad.2020.09.071. Epub 2020 Sep 23.

Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis

Anees Bahji  1 , Gustavo H Vazquez  2 , Carlos A Zarate Jr  3
Affiliations
Meta-Analysis

Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis

Anees Bahji et al. J Affect Disord. .

Erratum in

Abstract

Background: Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression. However, the comparative performance of different formulations of ketamine is less clear.

Objectives: This study aimed to assess the comparative efficacy and tolerability of racemic and esketamine for the treatment of unipolar and bipolar major depression.

Design: Systematic review and meta-analysis.

Data sources: We searched PubMed, MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Clinical Trials, and the Cochrane Database of Systematic Reviews for relevant studies published since database inception and December 17, 2019.

Study eligibility criteria: We considered randomized controlled trials examining racemic or esketamine for the treatment of unipolar or bipolar major depression.

Outcomes: Primary outcomes were response and remission from depression, change in depression severity, suicidality, retention in treatment, drop-outs, and drop-outs due to adverse events.

Analysis: Evidence from randomized controlled trials was synthesized as rate ratios (RRs) for treatment response, disorder remission, adverse events, and withdrawals and as standardized mean differences (SMDs) for change in symptoms, via random-effects meta-analyses.

Findings: 24 trials representing 1877 participants were pooled. Racemic ketamine relative to esketamine demonstrated greater overall response (RR = 3.01 vs. RR = 1.38) and remission rates (RR = 3.70 vs. RR = 1.47), as well as lower dropouts (RR = 0.76 vs. RR = 1.37).

Conclusions: Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression.

Keywords: Bipolar disorder; Depression; Depressive disorder; Esketamine; Ketamine; Major; Meta-analysis; Randomized controlled trials.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA flow diagram outlining the systematic review process.
Figure 2.
Figure 2.
Subgroup meta-analysis of response rates in the treatment of depression with racemic ketamine versus esketamine
Figure 3.
Figure 3.
Subgroup meta-analysis of remission rates in the treatment of depression with ketamine versus esketamine
Figure 4.
Figure 4.
Subgroup meta-analysis of depression rating scores in the treatment of depression with ketamine versus esketamine
Figure 5.
Figure 5.
Funnel plots and publication bias assessment for response rates (top left), remission rates (top right), depression rating scores (upper middle left), suicidality (upper middle right), completion (lower middle left), drop-outs (lower middle right), and drop-outs due to adverse events (bottom left)
Figure 6.
Figure 6.
Risk of bias summary
See this image and copyright information in PMC

Comment in

References

    1. Aan Het Rot M, Zarate CAJ, Charney DS, Mathew SJ, 2012. Ketamine for depression: where do we go from here? Biol. Psychiatry 72, 537–547. 10.1016/j.biopsych.2012.05.003 - DOI - PMC - PubMed
    1. Abdallah CG, Sanacora G, Duman RS, Krystal JH, 2015. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med. 66, 509–523. 10.1146/annurev-med-053013-062946 - DOI - PMC - PubMed
    1. Alberich S, Martínez-Cengotitabengoa M, López P, Zorrilla I, Núñez N, Vieta E, González-Pinto A, 2017. Efficacy and safety of ketamine in bipolar depression: A systematic review. Rev. Psiquiatr. Salud Ment. 10, 104–112. 10.1016/j.rpsm.2016.05.005 - DOI - PubMed
    1. Aleksandrova LR, Phillips AG, Wang YT, 2017. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J. Psychiatry Neurosci. JPN 42, 222–229. 10.1503/jpn.160175 - DOI - PMC - PubMed
    1. Arabzadeh S, Hakkikazazi E, Shahmansouri N, Tafakhori A, Ghajar A, Jafarinia M, Akhondzadeh S, 2018. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. J. Affect. Disord. 235, 236–241. 10.1016/j.jad.2018.02.056 - DOI - PubMed

MeSH terms